Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?
Yıl: 2019 Cilt: 11 Sayı: 3 Sayfa Aralığı: 171 - 177 Metin Dili: İngilizce DOI: 10.5222/iksstd.2019.77486 İndeks Tarihi: 04-03-2020
Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?
Öz: Objective: Amyloid A (AA) amyloidosis is the most prevalent form of systemic amyloidosis, and is a serious condition characterized by protein-misfolding. Cardiovascular involvement is known to be a significant manifestation of the disease and common carotid artery intima-media thickness (CIMT) assessment is one of the well-recognized tools for identification of subclinical atherosclerosis. It was reported that FGF-23 may be a significant factor associated with atherosclerosis development in patients with AA amyloidosis, as well as being an independent risk factor for increased CIMT. In this study, we aimed to investigate whether elevated FGF-23 levels might be associated with CIMT levels in AA amyloidosis patients. Method: We studied 63 patients with AA amyloidosis and 29 aged-matched healthy controls. All subjects’ demographic data were recorded and the following parameters were measured: erythrocyte sedimentation rate, C-reactive protein, creatinine, urea, albumin, calcium, phosphate, parathyroid hormone, FGF-23, eGFR, CIMT, blood pressure and BMI. Results: CIMT levels were significantly higher in AA amyloidosis patients compared to the control group (p<0.001). However, serum FGF-23 levels were similar (p=0.110). CIMT was correlated with patient age (r=0.471, p<0.001), but serum FGF-23 was not associated with CIMT in patients with amyloidosis (r=0.031, p=0.807). Conclusion: Although our results suggest a lack of association between FGF-23 levels and CIMT in patients with AA amyloidosis.
Anahtar Kelime: Konular:
AA Amiloidozlu Hastalarda Serum FGF-23 Düzeyi Subklinik Aterosklerozun Göstergesi midir?
Öz: Amaç: Amiloidoz proteinlerin anormal katlantı oluşturması ile karekterize hayatı tehdit eden bir hastalıktır, Amyloid-associated (AA) amiloidoz sistemik amiloidozun en yaygın formudur. Kardiyovasküler tutulum amiloidozun en önemli klinik tezahürüdür ve karotis intima media kalınlığının ölçümü (KIMK) subklinik aterosklerozu tespit etmek için iyi tanımlanmış yöntemlerden birisidir. FGF-23 AA amiloidozda KIMK’dan bağımsız olarak subklinik ateroskleroz ile ilişkili olabileceği bildirilmiştir. Bu çalışmada amacımız, AA amiloidozlu hastalarda KIMK ile yükselmiş serum FGF-23 ile ilişkisinin olup olmadığına bakmaktı. Yöntem: Çalışmaya 63 AA amiloidozlu hasta ve 29 sağlıklı kontrol dahil ettik. Tüm olguların demografik verileri, eritrosit sedimantasyon hızı, Crp, kreatinin, üre, albumin, kalsiyum, fosfat, parathormon, FGF-23, eGFR, KIMK, kan basıncı ve vücut kitle indeksleri kayıt edildi. Bulgular: Karotis intima media kalınlığı AA amiloidozlu hastalarda kontrol grubuna göre anlamlı derecede fazlaydı (p<0.001). Bununla birlikte serum FGF-23 seviyesi iki grup arasında farklı değildi (p =0.110). KIMK yaş ile köreleydi (r=0.471, p<0.001), fakat serum FGF-23 seviyesi amiloidozlu hastalarda KIMK ile körele değildi (r=0.031, p=0.807). Sonuç: Bizim çalışmamızda, AA amiloidozlu hastalarda KIMK ile Serum FGF-23 seviyesi arasında bir korelasyon tespit edilememiştir.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Immonen K, Finne P, Gronhagen-Riska C, Pettersson T, Klaukka T, Kautiainen H, et al. A marked decline in the incidence of renal replacement therapy for amyloido-sis associated with inflammatory rheumatic diseases - data from nationwide registries in Finland. Amyloid. 2011;18(1):25-8. https://doi.org/10.3109/13506129.2010.549252
- 2. Hazenberg BP, van Rijswijk MH. Where has secondary amyloid gone? Ann Rheum Dis. 2000;59(8):577-9. https://doi.org/10.1136/ard.59.8.577
- 3. McAdam KP, Raynes JG, Alpers MP, Westermark GT, Westermark P. Amyloidosis: a global problem common in Papua New Guinea. P N G Med J. 1996;39(4):284-96.
- 4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-18. https://doi.org/10.1097/01.ASN.0000133041.27682.A2
- 5. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16(6):1788-93. https://doi.org/10.1681/ASN.2004040275
- 6. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67(3): 1179-87. https://doi.org/10.1111/j.1523-1755.2005.00185.x
- 7. Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 produc-tion. J Biol Chem. 2003;278(4):2206-11. https://doi.org/10.1074/jbc.M207872200
- 8. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 2004;65(5):1943-6. https://doi.org/10.1111/j.1523-1755.2004.00604.x
- 9. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 miti-gates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7):2205-15. https://doi.org/10.1681/ASN.2005010052
- 10. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascu-lar disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21(2):93-111; quiz 89-90. https://doi.org/10.1016/j.echo.2007.11.011
- 11. Society of Atherosclerosis I, Prevention Developed in collaboration with the International Atherosclerosis S. Appropriate use criteria for carotid intima media thick-ness testing. Atherosclerosis. 2011;214(1):43-6. https://doi.org/10.1016/j.atherosclerosis.2010.10.045
- 12. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
- 13. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct mea-surement with ultrasound imaging. Circulation. 1986;74(6):1399-406. https://doi.org/10.1161/01.CIR.74.6.1399
- 14. Ugurlu S, Seyahi E, Cetinkaya F, Ozbakir F, Balci H, Ozdogan H. Intima-media thickening in patients with familial Mediterranean fever. Rheumatology (Oxford, England). 2009;48(8):911-5. https://doi.org/10.1093/rheumatology/kep131
- 15. Balci M, Kirkpantur A, Gulbay M, Gurbuz OA. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in main-tenance hemodialysis patients. Hemodial Int. 2010;14(4):425-32. https://doi.org/10.1111/j.1542-4758.2010.00480.x
- 16. Peru H, Altun B, Dogan M, Kara F, Elmaci AM, Oran B. The evaluation of carotid intima-media thickness in children with familial Mediterranean fever. Clin Rheumatol. 2008;27(6):689-94. https://doi.org/10.1007/s10067-007-0764-1
- 17. Akdogan A, Calguneri M, Yavuz B, Arslan EB, Kalyoncu U, Sahiner L, et al. Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF. J Am Coll Cardiol. 2006;48(11):2351-3. https://doi.org/10.1016/j.jacc.2006.09.013
- 18. Bilginer Y, Ozaltin F, Basaran C, Duzova A, Besbas N, Topaloglu R, et al. Evaluation of intima media thickness of the common and internal carotid arteries with inflammatory markers in familial Mediterranean fever as possible predictors for atherosclerosis. Rheumatol Int. 2008;28(12):1211-6. https://doi.org/10.1007/s00296-008-0605-9
- 19. Sari I, Karaoglu O, Can G, Akar S, Gulcu A, Birlik M, et al. Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever. Clin Rheumatol. 2007;26(9):1467-73. https://doi.org/10.1007/s10067-006-0529-2
- 20. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584-92. https://doi.org/10.1056/NEJMoa0706130
- 21. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009;24(9):2792-6. https://doi.org/10.1093/ndt/gfp191
- 22. Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calci-fication in haemodialysis patients. Nephrol Dial Transplant. 2010;25(8):2679-85. https://doi.org/10.1093/ndt/gfq089
- 23. Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calci-fication. Kidney Int. 2013;83(6):1159-68. https://doi.org/10.1038/ki.2013.3
- 24. Hu X, Ma X, Luo Y, Xu Y, Xiong Q, Pan X, et al. Elevation in fibroblast growth factor 23 and its value for identify-ing subclinical atherosclerosis in first-degree relatives of patients with diabetes. Sci Rep. 2016;6:34696. https://doi.org/10.1038/srep34696
- 25. Biscetti F, Straface G, Porreca CF, Bertoletti G, Vincenzoni C, Snider F, et al. Increased FGF23 serum level is associated with unstable carotid plaque in type 2 diabetic subjects with internal carotid stenosis. Cardiovasc Diabetol. 2015;14:139. https://doi.org/10.1186/s12933-015-0301-5
- 26. Schoppet M, Hofbauer LC, Brinskelle-Schmal N, Varennes A, Goudable J, Richard M, et al. Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. The Journal of clinical endocrinology and metab-olism. 2012;97(4):E575-83. https://doi.org/10.1210/jc.2011-2836
- 27. Shah NH, Dong C, Elkind MS, Sacco RL, Mendez AJ, Hudson BI, et al. Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area: The Northern Manhattan Study. Arterioscler Thromb Vasc Biol. 2015;35(9):2048-53. https://doi.org/10.1161/ATVBAHA.115.305945
- 28. Nakayama M, Kaizu Y, Nagata M, Ura Y, Ikeda H, Shimamoto S, et al. Fibroblast growth factor 23 is asso-ciated with carotid artery calcification in chronic kid-ney disease patients not undergoing dialysis: a cross-sectional study. BMC Nephrol. 2013;14:22. https://doi.org/10.1186/1471-2369-14-22
- 29. Modesto KM, Dispenzieri A, Gertz M, Cauduro SA, Khandheria BK, Seward JB, et al. Vascular abnormali-ties in primary amyloidosis. Eur Heart J. 2007;28(8):1019-24. https://doi.org/10.1093/eurheartj/ehm066
- 30. Keles N, Caliskan M, Aksu FU, Keles NN, Karagoz V, Tekin AS, et al. Retrobulbar blood flow and carotid intima-media thickness alteration may relate to sub-clinic atherosclerosis in patients with chronic inflam-matory diseases. Renal Failure. 2015;37(7):1164-70. https://doi.org/10.3109/0886022X.2015.1057469
| APA | Bakan A, Oral A, OZKOK A, ALIŞIR ECDER S, ELÇİOĞLU Ö, ŞAŞAK KUZGUN G, AYDIN BAHAT K, Odabas A (2019). Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?. , 171 - 177. 10.5222/iksstd.2019.77486 |
| Chicago | Bakan Ali,Oral Alihan,OZKOK ABDULLAH,ALIŞIR ECDER Sabahat,ELÇİOĞLU Ömer Celal,ŞAŞAK KUZGUN Gülşah,AYDIN BAHAT Kübra,Odabas Ali Rıza Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?. (2019): 171 - 177. 10.5222/iksstd.2019.77486 |
| MLA | Bakan Ali,Oral Alihan,OZKOK ABDULLAH,ALIŞIR ECDER Sabahat,ELÇİOĞLU Ömer Celal,ŞAŞAK KUZGUN Gülşah,AYDIN BAHAT Kübra,Odabas Ali Rıza Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?. , 2019, ss.171 - 177. 10.5222/iksstd.2019.77486 |
| AMA | Bakan A,Oral A,OZKOK A,ALIŞIR ECDER S,ELÇİOĞLU Ö,ŞAŞAK KUZGUN G,AYDIN BAHAT K,Odabas A Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?. . 2019; 171 - 177. 10.5222/iksstd.2019.77486 |
| Vancouver | Bakan A,Oral A,OZKOK A,ALIŞIR ECDER S,ELÇİOĞLU Ö,ŞAŞAK KUZGUN G,AYDIN BAHAT K,Odabas A Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?. . 2019; 171 - 177. 10.5222/iksstd.2019.77486 |
| IEEE | Bakan A,Oral A,OZKOK A,ALIŞIR ECDER S,ELÇİOĞLU Ö,ŞAŞAK KUZGUN G,AYDIN BAHAT K,Odabas A "Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?." , ss.171 - 177, 2019. 10.5222/iksstd.2019.77486 |
| ISNAD | Bakan, Ali vd. "Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?". (2019), 171-177. https://doi.org/10.5222/iksstd.2019.77486 |
| APA | Bakan A, Oral A, OZKOK A, ALIŞIR ECDER S, ELÇİOĞLU Ö, ŞAŞAK KUZGUN G, AYDIN BAHAT K, Odabas A (2019). Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?. İstanbul Kanuni Sultan Süleyman Tıp Dergisi, 11(3), 171 - 177. 10.5222/iksstd.2019.77486 |
| Chicago | Bakan Ali,Oral Alihan,OZKOK ABDULLAH,ALIŞIR ECDER Sabahat,ELÇİOĞLU Ömer Celal,ŞAŞAK KUZGUN Gülşah,AYDIN BAHAT Kübra,Odabas Ali Rıza Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?. İstanbul Kanuni Sultan Süleyman Tıp Dergisi 11, no.3 (2019): 171 - 177. 10.5222/iksstd.2019.77486 |
| MLA | Bakan Ali,Oral Alihan,OZKOK ABDULLAH,ALIŞIR ECDER Sabahat,ELÇİOĞLU Ömer Celal,ŞAŞAK KUZGUN Gülşah,AYDIN BAHAT Kübra,Odabas Ali Rıza Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?. İstanbul Kanuni Sultan Süleyman Tıp Dergisi, vol.11, no.3, 2019, ss.171 - 177. 10.5222/iksstd.2019.77486 |
| AMA | Bakan A,Oral A,OZKOK A,ALIŞIR ECDER S,ELÇİOĞLU Ö,ŞAŞAK KUZGUN G,AYDIN BAHAT K,Odabas A Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?. İstanbul Kanuni Sultan Süleyman Tıp Dergisi. 2019; 11(3): 171 - 177. 10.5222/iksstd.2019.77486 |
| Vancouver | Bakan A,Oral A,OZKOK A,ALIŞIR ECDER S,ELÇİOĞLU Ö,ŞAŞAK KUZGUN G,AYDIN BAHAT K,Odabas A Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?. İstanbul Kanuni Sultan Süleyman Tıp Dergisi. 2019; 11(3): 171 - 177. 10.5222/iksstd.2019.77486 |
| IEEE | Bakan A,Oral A,OZKOK A,ALIŞIR ECDER S,ELÇİOĞLU Ö,ŞAŞAK KUZGUN G,AYDIN BAHAT K,Odabas A "Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?." İstanbul Kanuni Sultan Süleyman Tıp Dergisi, 11, ss.171 - 177, 2019. 10.5222/iksstd.2019.77486 |
| ISNAD | Bakan, Ali vd. "Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?". İstanbul Kanuni Sultan Süleyman Tıp Dergisi 11/3 (2019), 171-177. https://doi.org/10.5222/iksstd.2019.77486 |
